Choice Health exhibited at the UKIO conference last month where it showcased its services, including newly commissioned research clinical trial imaging support for the NHS. Greenan with Intelerad Medical Systems president Morris Panner and Choice Health medical director Dr Riz Basit. “Immense pressures are placed on imaging departments, with yearly demand increasing in clinical activity,” states the company.
“It is not surprising that participation in clinical trial research is often seen as a lower priority, with requests to participate declined due to a mixture of personnel, capacity, regulatory and logistics shortfalls.
“As a result, NHS trusts are struggling to participate in drug development clinical trials, with many of these research studies involving experimental investigational medicinal products with oncology applications that could really benefit patients.”
Choice Health says it has a proven track record in the clinical trial imaging field, working with pharma, biotechnology and contract research organisations delivering consulting, regulatory and image analysis to assist drug development.
Lead picture: Choice Health ceo Pauric Greenan with consultant radiologists Dr Rizwan Malik and Dr Rhidian Bramley.
See this report on page 14 of the August 2022 issue of RAD Magazine.